Get access

Maintenance bioimmunotherapy for epithelial ovarian cancer

  • Protocol
  • Intervention

Authors

  • Ling Mei,

    1. West China Second University Hospital, West China Women's and Children's Hospital, Department of Obstetrics and Gynecology, Chengdu, Sichuan, China
    Search for more papers by this author
  • Hui Chen,

    1. West China Second University Hospital, West China Women's and Children's Hospital, Department of Obstetrics and Gynecology, Chengdu, Sichuan, China
    Search for more papers by this author
  • Fuxia Chen,

    1. West China Second University Hospital, West China Women's and Children's Hospital, Department of Obstetrics and Gynecology, Chengdu, Sichuan, China
    Search for more papers by this author
  • Dan Feng,

    1. West China Second University Hospital, West China Women's and Children's Hospital, Department of Obstetrics and Gynecology, Chengdu, Sichuan, China
    Search for more papers by this author
  • Fang Fang

    Corresponding author
    1. West China Second University Hospital, West China Women's and Children's Hospital, Department of Obstetrics and Gynecology, Chengdu, Sichuan, China
    • Fang Fang, Department of Obstetrics and Gynecology, West China Second University Hospital, West China Women's and Children's Hospital, No. 17, Section Three, Ren Min Nan Lu Avenue, Chengdu, Sichuan, 610041, China. ffmn59@163.com.

    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the effectiveness and toxicity of maintenance bioimmunotherapy available for epithelial ovarian cancer and to evaluate the impact on the quality of life (QoL) of maintenance bioimmunotherapy. We will update this review once new treatments are available, but the first step is to evaluate interferon-alpha, matrix metalloprotease inhibitor, monoclonal antibodies, and some radioimmunotherapies, which have been studied by phase trials.